Treatment patterns, clinical outcomes, and healthcare resource use associated with advanced/metastatic lung cancer in China: protocol for a retrospective observational study

Bin Qiu, Gaofeng Li, Feng Luo, Xiaohong Cai, Lin Wu, Jianhua Chen, Yanping Hu, Zhiliu Tang, Shuo Yang, Jie He, Bin Qiu, Gaofeng Li, Feng Luo, Xiaohong Cai, Lin Wu, Jianhua Chen, Yanping Hu, Zhiliu Tang, Shuo Yang, Jie He

Abstract

Background: Lung cancer (LC) is the most common cancer worldwide. The prevalence of LC and rate of associated mortality are high and increasing faster in China than in Western countries. Non-small cell lung cancer (NSCLC) accounts for most LCs. This study aims to be the first large, multi-center, non-interventional retrospective study of treatment patterns (type/duration, number of lines, completion rate), real-world outcomes, and medical costs among Chinese patients with advanced/metastatic NSCLC (IIIb/IV) or extensive-stage small cell LC (ES-SCLC).

Methods: This study will enroll 8,800 patients (≥18 years, with a diagnosis of advanced/metastatic NSCLC made between 1 December 2013 to 30 November 2014) from 35 to 50 Chinese sites. Hospital information systems (HIS) and electronic medical records will be retrospectively reviewed, in adherence with regulatory and ethical requirements. Early-stage treatment (starting from 1 December 2010) of patients with recurrent disease or early disease progression will be examined. Data will be collected at baseline (diagnosis) and 6 and 12 months after this. Observation will end after 3 years or death. Data will be stratified by histology, staging, age, region, health insurance, and epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) mutation status. Treatment duration and overall survival will be estimated using Kaplan-Meier curves. Descriptive statistics will be used for disease characteristics and patient demographics. Cox-proportional hazards models will be used to examine the impact of demographics/treatment on survival. Treatment patterns and outcome predictors will be explored using multivariate logistic regression.

Discussion: This protocol describes the methodology for collecting real-world data to guide evidence-based clinical practice and inform unmet needs in NSCLC treatment, with potential to identify gaps between guidelines and current practice.

Trial registration: NCT03505515; data registered on ClinicalTrials.gov: 12h Apr., 2018.

Keywords: China; clinical protocol; lung neoplasms.

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-1269). ZT was employed by Bristol-Myers Squibb at the time the manuscript was prepared, and SY is employed by Bristol-Myers Squibb. The other authors have no conflicts of interest to declare.

2020 Translational Lung Cancer Research. All rights reserved.

Figures

Figure 1
Figure 1
Study timeline for patients with an initial diagnosis of late-stage cancer.
Figure 2
Figure 2
Depiction of the patient screening and data extraction process.

References

    1. Chen W, Zheng R, Zeng H, et al. Epidemiology of lung cancer in China. Thorac Cancer 2015;6:209-15. 10.1111/1759-7714.12169
    1. Zheng R, Zeng H, Zuo T, et al. Lung cancer incidence and mortality in China, 2011. Thorac Cancer 2016;7:94-9. 10.1111/1759-7714.12286
    1. Fan H, Shao ZY, Xiao YY, et al. Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study. BMJ Open 2015;5:e009419. 10.1136/bmjopen-2015-009419
    1. Zheng XQ, Huang JF, Lin JL, et al. Incidence, prognostic factors, and a nomogram of lung cancer with bone metastasis at initial diagnosis: a population-based study. Transl Lung Cancer Res 2019;8:367-79. 10.21037/tlcr.2019.08.16
    1. Institute NC. Surveillance, Epidemiology, and End Results (SEER) Program. 2014. Available online: . Accessed 14 January 2020 2020.
    1. Ulrich BC, Guibert N. Immunotherapy efficacy and gender: discovery in precision medicine. Transl Lung Cancer Res 2018;7:S211-3. 10.21037/tlcr.2018.08.05
    1. Ettinger DS, Aisner DL, Wood DE, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw 2018;16:807-21. 10.6004/jnccn.2018.0062
    1. Shi Y, Sun Y, Yu J, et al. China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version). Zhongguo Fei Ai Za Zhi 2016;19:1-15.
    1. Liu J, Cheng Y, Li H, et al. Current status of small cell lung cancer in China. Journal of Cancer Biology & Research 2014;2:1032-36.
    1. Yang LL, Zhang XC, Yang XN, et al. Lung cancer treatment disparities in China: a question in need of an answer. Oncologist 2014;19:1084-90. 10.1634/theoncologist.2014-0007
    1. Shi Y, Xing P, Fan Y, et al. Current small cell lung cancer treatment in China. Thorac Cancer 2015;6:233-8. 10.1111/1759-7714.12218
    1. Wu M, Wang Y, An T, et al. Analysis of prognostic factors in 541 female patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2011;14:245-50.
    1. Zhang C, Wang L, Li W, et al. Surgical outcomes of stage IV non-small cell lung cancer: a single-center experience. J Thorac Dis 2019;11:5463-73. 10.21037/jtd.2019.11.30
    1. Peng H, Han HB, Li XQ, et al. Analysis of clinical characteristics and survival of 1279 patients with lung cancer. Chinese Journal of Lung Cancer 2011;21:354-8.
    1. Wang L, He Z, Yang S, et al. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial. Transl Lung Cancer Res 2019;8:575-83. 10.21037/tlcr.2019.09.21
    1. Zhou T, Wu C, Zhang C, et al. A retrospective study of low-dose apatinib combined with S-1 in patients with advanced non-small cell lung cancer. J Thorac Dis 2019;11:1831-7. 10.21037/jtd.2019.05.33
    1. Dong K, Liang W, Zhao S, et al. EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases. Transl Lung Cancer Res 2019;8:268-79. 10.21037/tlcr.2019.06.12
    1. Gu YY. Epidemiology characteristics and disease burden of lung cancer patients with Shanghai identity [Dissertation]: Fu Dan University; 2013.
    1. Fan XH, Feng Y, Shao W, et al. Application and outcome of clinical pathway in radio- and chemo-therapy in lung cancer patients. Chinese Hospital Management 2011;2:25-7.
    1. Chen Z. Inpatient surgery cost structure and trend analysis of nearly 10,000 lung cancer patients. Chinese Health Research 2013;3:3.
    1. Du W, Zhang X, Gao C, et al. New grey correlation analysis of hospitalization expenses of 600 patients with non-small cell lung cancer. Journal of Shanghai Jiaotong University (Medical Science) 2012;10:1356-9.
    1. Gao YX, Xiao J, Wu XM, et al. Factor analysis of direct inpatient cost of 1666 lung cancer patients. Chinese Journal of Health Statistics 2011;3:278-80.
    1. Ding TT, Zhang X, Gao C, et al. Impact analysis and cost control research on inpatient medical cost of patients with non-small cell lung cancer. Chinese Journal of Health Statistics 2012;2:240-2.
    1. Gao YX, Yang M, Liu G, et al. Path analysis of impact factors of inpatient medical cost of patients with lung cancer. Chinese Journal of Public Health 2012:253-4.
    1. Shang M. Economic burden and impact factors of inpatient lung cancer patients [Dissertation]: Shandong University 2013.
    1. Gao QQ, Li SX, Wang Y, et al. Impact analysis of inpatient cost in lung cancer patients who underwent surgery using Grey relational method. Health Economics Research 2013;12:56-8.
    1. Lv HL, Zhao SF, Xie XP, et al. Impact analysis of inpatient cost of 16,866 lung cancer patients in Si Chuan Province. Chinese Journal of Evidence-Based Medicine 2013;11:1283-7.
    1. Gong H, Liu Y, Ma L, et al. Inpatient cost analysis of patients with lung cancer and liver cancer from 1996 to 2006 in Lanzhou City. Modern Preventive Medicine 2012;39:270-2.
    1. Zhou C. Lung cancer molecular epidemiology in China: recent trends. Transl Lung Cancer Res 2014;3:270-9.
    1. Toyoda Y, Nakayama T, Ioka A, et al. Trends in lung cancer incidence by histological type in Osaka, Japan. Jpn J Clin Oncol 2008;38:534-9. 10.1093/jjco/hyn072
    1. Thun MJ, Lally CA, Flannery JT, et al. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997;89:1580-6. 10.1093/jnci/89.21.1580
    1. Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117:294-9. 10.1002/ijc.21183
    1. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015;5:2892-911.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅